FierceBiotech

PRESS RELEASE: Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing

BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
News Medical

Test document

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
ascopubs.org

A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy

Does one person provide it all? Defining the social support of women with cancer Pts with adverse events - n (%) 46 (79) 49 (88) 95 (83) Pts with serious adverse events - n (%) 18 (31) 21 (38) 39 (34) ...
ascopubs.org

Guideline Summary: Use of Epoetin and Darbepoetin in Patients With Cancer–2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice ...

View all available purchase options and get full access to this article.
Monthly Prescribing Reference

Positive Data from Aranesp MDS Study Announced

The study showed patients treated with Aranesp had a reduction in the number of red blood cell transfusions Amgen announced positive results from the Phase 3 ARCADE study evaluating Aranesp ...
Nature

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...